Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), By Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), By End User (Hospitals, Cancer Research Centers, and Others), and By Region - Trends, Analysis and Forecast till 2034

• Amgen, Inc.
• AstraZeneca, PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lily And Company
• F. Hoffmann-La Roche, Ltd
• Pfizer, Inc.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Immunocore, Ltd.

 

Recent News:

• A new phase 2 study for pancreatic cancer began in June 2024, examining a triple-drug combination. The University of Glasgow and NHS Greater Glasgow and Clyde have launched a mid-stage trial to investigate a new medication combination as a first-line treatment for patients with metastatic pancreatic cancer. The phase 2 PRIMUS-006 study, part of the Precision-Panc Platform, will compare Eli Lilly and Genentech's Gemzar (gemcitabine) to Merck & Co's Keytruda (pembrolizumab), known as MSD outside the United States and Canada, and Immodulon Therapeutics' investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
• The first homegrown cell therapy for cancer treatment will be disclosed in April 2024, bringing hope. President Droupadi Murmu launched India's first indigenously developed CAR T-cell therapy for cancer treatment, describing it as a "breakthrough" that will give humanity new hope in the fight against the disease. NexCAR19 CAR T-cell therapy is the country's first 'Made in India' cell therapy, and it will significantly lower cancer treatment expenses. This gene-based therapy, developed by IIT Bombay and the Tata Memorial Centre, attempts to cure various cancers.